• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Ann Thorac Surg . Multi-institutional Analysis of 505 COVID-19 Patients Supported with ECMO: Predictors of Survival

tetano

Editor, Senior Moderator
Ann Thorac Surg


. 2022 Feb 18;S0003-4975(22)00198-9.
doi: 10.1016/j.athoracsur.2022.01.043. Online ahead of print.
Multi-institutional Analysis of 505 COVID-19 Patients Supported with ECMO: Predictors of Survival


Celeste A Hall[SUP] 1 [/SUP], Jeffrey P Jacobs[SUP] 2 [/SUP], Alfred H Stammers[SUP] 3 [/SUP], James D St Louis[SUP] 4 [/SUP], J W Awori Hayanga[SUP] 5 [/SUP], Michael S Firstenberg[SUP] 6 [/SUP], Linda B Mongero[SUP] 3 [/SUP], Eric A Tesdahl[SUP] 3 [/SUP], Keshava Rajagopal[SUP] 7 [/SUP], Faisal H Cheema[SUP] 8 [/SUP], Kirti Patel[SUP] 3 [/SUP], Tom Coley[SUP] 3 [/SUP], Anthony K Sestokas[SUP] 3 [/SUP], Marvin J Slepian[SUP] 9 [/SUP], Vinay Badhwar[SUP] 5 [/SUP]



Affiliations

Abstract

Background: We reviewed our experience with 505 patients with confirmed COVID-19 supported with ECMO at 45 hospitals and estimated risk factors for mortality.
Methods: A multi-institutional database was created and utilized to assess all patients with COVID-19 who were supported with ECMO. A Bayesian mixed-effects logistic regression model was estimated to assess the effect on survival of days between COVID-19 diagnosis and intubation, as well as age at ECMO cannulation.
Results: Median time on ECMO was 18 days (interquartile range=10-29). All 505 patients have separated from ECMO: 194 patients (38.4%) survived and 311 patients (61.6%) died. Survival with veno-venous ECMO was 184 of 466 patients (39.5%), while survival with veno-arterial ECMO was 8 of 30 patients (26.7%). Survivors had lower median age (44 versus 51 years, p<0.001) and shorter median time interval from diagnosis to intubation (7 days versus 11 days, p=0.001). Adjusting for several confounding factors, we estimated that an ECMO patient intubated on day 14 post COVID-19 diagnosis vs day 4 had a relative odds of survival of 0.65 (95% Credible Interval [CrI]:0.44-0.96, posterior probability of negative effect: 98.5%). Age was also negatively associated with survival: relative to a 38-year-old we estimated that a 57-year-old patient had a relative odds of survival of 0.43 (95% CrI:0.30-0.61, posterior probability of negative effect: >99.99%).
Conclusions: ECMO facilitates salvage and survival of select critically ill patients with COVID-19. Survivors tend to be younger and have shorter time from diagnosis to intubation. Survival of patients supported with only veno-venous ECMO was 39.5%.

Keywords: COVID-19; Coronavirus; Extracorporeal Membrane Oxygenation; Pulmonary failure; acute respiratory distress syndrome.
 
Back
Top Bottom